Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740103 · ClinicalTrials.gov registry record · Phase 2
Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT00740103 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 119 participants.
The verdict
NCT00740103, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Activity Index (CDAI).
Interventions
- DRUG Semapimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2002-12 |
| Est. Completion | 2004-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00740103
The ClinicalTrials.gov registry entry for NCT00740103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semapimod is the first listed.
NCT00740103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00740103 about?
NCT00740103 is a clinical study titled "Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease". CNI-1493-CD05 is an open-label extension study of CNI-1493-CD04. In the CD05 study, patients are eligible for up to 5 courses of semapimod 60 mg IV x 3 days every 6 - 8 weeks. Primary objective is assessment of the efficacy of cumulative doses of semapimod measured by decrease in Crohn's Disease Act...
What is the current status of trial NCT00740103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2002-12. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00740103?
The interventions under investigation include: Semapimod (DRUG).
Who is sponsoring clinical trial NCT00740103?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.